An experienced Scientist with broad industry exposure and a strong focus on Medical Genetics. David's high impact work on molecular diagnostics, therapeutics and prognostics of genetically associated cancers has contributed to esteemed publications in journals such as The New England Journal of Medicine, amongst others. Emerging from an academic background founded on research into the hereditary predisposition to cancer, the molecular and biochemical basis of cancer pathogenesis, compound biochemistry and the pharmcogenomic response of DNA repair mechanism targeted therapeutics, David has gone on to become a productive member of the biotechnology community. David’s years of industry experience has allowed for an evolution of his skill set, which he now leverages in his role leading investments in North American healthcare public equities. In 2020, Mr. Novak was nominated as a “top 40 under 40” candidate by the Investment Industry of Canada. Additionally, he has been a leading source of biotechnology insight, appearing on CNBC, BNN/Bloomberg, CBC, and in various written media formats. Specialties: Hereditary basis of Oncology, Medical Genetics, Tumorgenesis biochemistry, Predisposition marker identification, Scientific Communication, Project Management, Clinical Affairs An experienced Scientist with broad industry exposure and a strong focus on Medical Genetics. David's high impact work on molecular diagnostics, therapeutics and prognostics of genetically associated cancers has contributed to esteemed publications in journals such as The New England Journal of Medicine, amongst others. Emerging from an academic background founded on research into the hereditary predisposition to cancer, the molecular and biochemical basis of cancer pathogenesis, compound biochemistry and the pharmcogenomic response of DNA repair mechanism targeted therapeutics, David has gone on to become a productive member of the biotechnology community. David’s years of industry experience has allowed for an evolution of his skill set, which he now leverages in his role leading investments in North American healthcare public equities. In 2020, Mr. Novak was nominated as a “top 40 under 40” candidate by the Investment Industry of Canada. Additionally, he has been a leading source of biotechnology insight, appearing on CNBC, BNN/Bloomberg, CBC, and in various written media formats. Specialties: Hereditary basis of Oncology, Medical Genetics, Tumorgenesis biochemistry, Predisposition marker identification, Scientific Communication, Project Management, Clinical Affairs

• 

  Venture Partner in Lumira Ventures

  Our mission is to deliver exceptional returns for investors by investing in and helping to create value in transformative life sciences companies.